The United States Food and Drug Administration (FDA) has granted Kiadis Pharma orphan drug designation for their product ATIR for the prevention of Graft-versus-Host-Disease (GVHD).
ATIR is the lead product for Kiadis Pharma and was designed to prevent the development of GVHD among patients undergoing an allogeneic bone marrow transplant.
ATIR selectively eliminates donor immune cells that are responsible for GVHD, while allowing donor immune cells that are fighting cancer and restoring blood cell levels to remain. The intent is to allow for mismatched donors to be used for an allogeneic transplant so that patients don’t die while waiting for a matched donor, or are at a significant risk for GVHD.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
